Clinical trial validates bioengineered blood vessels for trauma surgery
Phase II trial demonstrates superior outcomes compared to synthetic grafts in both civilian and military settings, with significantly lower amputation rates and infection risks.
Phase II trial demonstrates superior outcomes compared to synthetic grafts in both civilian and military settings, with significantly lower amputation rates and infection risks.
A European research initiative has made significant progress in identifying new treatments to protect heart muscle during acute cardiac events, with potential implications for both diabetic and non-diabetic patients.
In an historic achievement, Dr. Feras Khaliel and his team at King Faisal Specialist Hospital & Research Centre (KFSHRC) in Riyadh, Saudi Arabia, successfully performed the world’s first fully robotic heart transplant on a 16-year-old patient with end-stage heart failure. This innovative procedure reduced recovery times and surgical risks, setting a new standard for cardiac […]
A study from Karolinska Institutet reveals that low levels of anti-phosphorylcholine antibodies may indicate increased risk of heart disease in older women, potentially paving the way for improved risk assessment and preventive strategies.
The American Heart Association and American College of Cardiology have jointly published an updated guideline for managing cardiovascular risks in patients undergoing noncardiac surgery, reflecting a decade of new evidence since the last update in 2014.
New research reveals that patients with stable coronary artery disease who quit smoking at any point after diagnosis can reduce their risk of major cardiovascular events by nearly 50%. The study, presented at ESC Congress 2024, also found that merely reducing smoking habits had minimal impact on cardiovascular risk.
A series of groundbreaking studies from Poland have shed new light on the prevalence and impact of lipoprotein(a) [Lp(a)] on cardiovascular health, prompting calls for routine measurement of this important biomarker.
A groundbreaking titanium artificial heart with a single moving part has been successfully implanted in a patient with end-stage heart failure, potentially revolutionising treatment options for those awaiting transplantation.
Royal Philips has announced the successful first implantation of its Duo Venous Stent System following premarket approval from the U.S. Food and Drug Administration. The device is indicated for treating symptomatic venous outflow obstruction in patients with chronic venous insufficiency (CVI).
Royal Philips, a leader in health technology, has launched a new cardiac care platform aimed at transforming diagnostic cardiology in Europe, the Middle East, and Africa. The Philips Cardiac Workstation utilises sophisticated algorithms to expedite the collection and processing of electrocardiograph (ECG) data, potentially streamlining care and helping to prioritise high-risk patients.
April 2024
The medical devices information portal connecting healthcare professionals to global vendors
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com
PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlyCookie settingsWe may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.
Privacy policy